IPP Bureau
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
By IPP Bureau - August 04, 2022
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
LYNPARZA approved in the EU as adjuvant treatment for early breast cancer
By IPP Bureau - August 04, 2022
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr
By IPP Bureau - August 03, 2022
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr
By IPP Bureau - August 03, 2022
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma
By IPP Bureau - August 03, 2022
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
PIB: Quality control of Ayush drugs
By IPP Bureau - August 03, 2022
PIB: Budget allocation and utilization of funds under National Ayush Mission
By IPP Bureau - August 03, 2022
The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.
PIB: Development of Ayush entrepreneurship
By IPP Bureau - August 03, 2022
Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.
Ensure time-bound Infrastructure development of Ayush National Institutes/Central Councils projects: Sonowal
By IPP Bureau - August 03, 2022
Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country
PIB: Pharmaceutical industry in Maharashtra
By IPP Bureau - August 03, 2022
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
PIB: Pharma companies manufacturing generic medicine
By IPP Bureau - August 03, 2022
Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.
PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.
By IPP Bureau - August 03, 2022
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
Jubilant Pharmova gets 6 observations from USFDA for its facility at Roorkee
By IPP Bureau - August 03, 2022
he US FDA has issued six observations pursuant to the completion of the audit.
USFDA issues 3 observations for Aurobindo Pharma’s Unit XI
By IPP Bureau - August 03, 2022
The company has responded to the warning letter and carried out the committed corrections.
Sun Pharma Chairman Israel Makov to retire on completion of term
By IPP Bureau - August 03, 2022
He was appointed a Board member and the Chairman in 2012.
